References
- Han JH, Goldstein EJC, Wise J, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae in a network of long-term acute care hospitals. Clin Infect Dis 2017;64:839–44.
- Hussein K, Bitterman R, Shofty B, Paul M, Neuberger A. Management of post-neurosurgical meningitis: narrative review. Clin Microbiol Infect 2017;23:621–8.
- Centers for Disease Control and Prevention. Antimicrobial resistance threats in the United States; 2013[EB/OL]. [2016-07-01]. Available from:http://www.cdc.gov/drugresistance/threat-report-2013/index/html.
- Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30:972–6.
- Mermer S, Aydemir S, Ozgiray E, Sipahi OR. Carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. J Chemother 2016;28:454–5.
- Emiroglu M, Alkan G, Dagi HT. Tigecycline therapy in an infant for ventriculoperitoneal shunt meningitis. Pediatrics 2017;139:e20160963.
- Holyk A, Belden V, Lee JJ, et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. J Antimicrob Chemother 2017;73:254–6.
- Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:785–96.
- Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016;63:1615–8.
- Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis 2017;64:e34–65.
- Brouwer MC, Coutinho JM, van de Beek D. Clinical characteristics and outcome of brain abscess systematic review and meta-analysis. Neurology 2014;82:806–13.